VANDERBILT UNIVERSITY MEDICAL CENTER
Selective loss of HLA gene products in driving unique breast cancer immunobiology
Selective loss of HLA gene products in driving unique breast cancer immunobiology is a funding opportunity from VANDERBILT UNIVERSITY MEDICAL CENTER, up to 695884, closing May 31, 2031.
May 31, 2031
(1765d left)Overview
Despite the success of immune checkpoint inhibition (ICI) in cancer therapy, intrinsic and acquired resistance to therapy are common in triple-negative breast cancer (TNBC) patients and the mechanisms are poorly understood. CD8+ cytotoxic T cell recognition of MHC-I-peptide complexes (pMHC-I) is critical for response…